GlassScriptPhysician profile
Elaini Ruth Hall
NPI 1639833080
$2,925.01
in general payments reported to CMS, 2019-2025
25 companies · $53.43 in 2025
The $53.43 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $387 · 2023: $2,073 · 2024: $411 · 2025: $53.43.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,538.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,537.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $708.06 | 2022-2025 | |
| Novo Nordisk INC | $619.31 | 2022-2023 | Rybelsus, Ozempic, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $235.06 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $232.42 | 2023-2025 | Airsupra, Farxiga |
| Lilly USA, LLC | $156.25 | 2022-2023 | Mounjaro, Jardiance, Trulicity |
| Sanofi-Aventis U.S. LLC | $145.33 | 2022-2023 | |
| Silk Road Medical, INC. | $136.77 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter, Enroute Transcarotid Stent |
| Janssen Pharmaceuticals, INC | $104.76 | 2023 | Xarelto |
| Xeris Pharmaceuticals, INC. | $72.51 | 2022-2023 | Gvoke Hypopen |
| Amgen INC. | $70.70 | 2023 | Otezla, Repatha, Prolia |
| Pfizer INC. | $70.25 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $56.50 | 2022-2023 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $55.37 | 2023 | Trulance, Xifaxan |
| Medtronic, INC. | $42.13 | 2023 | Minimed 780g |
| Merck Sharp & Dohme LLC | $33.30 | 2023 | Verquvo, Belsomra |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intra-Sana Laboratories | $27.04 | 2023 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Lundbeck LLC | $22.84 | 2023 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.01 | 2022 | |
| Dexcom, INC. | $20.55 | 2023 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $19.34 | 2023 | Trelegy Ellipta, Shingrix |
| Alexion Pharmaceuticals, INC. | $17.13 | 2023 | Strensiq |
| Boston Scientific Corporation | $15.42 | 2025 | General - Erectile Dysfunction |
| Shield Therapeutics INC | $14.96 | 2023 | Accrufer |
| E.R. Squibb & Sons, L.L.C. | $14.21 | 2023 | |
| Novartis Pharmaceuticals Corporation | $13.79 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elaini Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.